Frontage ran a Phase I Study of OMN54 (Aneustat™) in patients with advanced malignancies.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
This webinar discusses smart processes to include in your Phase 1 clinical development program to save time and cost yet add value to your clinical asset. Cut time, not corners.
Strategies and Solutions for Early Phase Formulation Development and CTM Manufacturing
In this webinar, we discuss the strategies to overcome challenges during formulation development, various technologies available for formulation development, and Frontage CMC's unique capabilities.
Speaker: Manish Munjal is a Director of Product Development and Clinical Trial Material Manufacturing at Frontage Laboratories. With over 12 years of pharmaceutical drug development experience, his expertise spans pre-formulation, formulation, and process development leading to exhibit/clinical batches for FDA submission. Dr. Munjal also served as a member of Nycomed Technical Operations division, where he managed technical investigations on commercial products, and was instrumental in bringing key products back to the commercial landscape. In his current position at Frontage, he oversees product development groups engaged in sterile (injectables, ophthalmics, inhalation) and non-sterile (oral solid and liquid, topical) drug development and manufacturing.
Sequencing the bacterial 16S rRNA gene is an established technique for assessing the phylogenetic diversity of microbial communities. This white paper discusses the methods and process to elucidate that Frontage’s QIIME2 analysis pipeline accurately estimates the composition of microbiome samples, as shown by the similarity to the theoretical abundance.